Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008;13(3):465-74.
doi: 10.2478/s11658-008-0014-9. Epub 2008 May 6.

Lipid changes occuring in the course of hematological cancers

Affiliations

Lipid changes occuring in the course of hematological cancers

Małgorzata Kuliszkiewicz-Janus et al. Cell Mol Biol Lett. 2008.

Abstract

The relationship between plasma lipid levels and mortality from cardiovascular diseases has been shown in many studies, but there has been far less investigation into their relationship to non-cardiovascular diseases. The aim of this study was to investigate the lipid profile of individuals with hematological malignancies and its relationship to disease activity. 238 patients were included in the study: 84 with acute leukemia, 62 with non-Hodgkin lymphoma, 35 with Hodgkin's lymphoma, 32 with multiple myeloma, and 25 with myeloproliferative syndrome. The HDL cholesterol level of the patients differed to that of the individuals in the control group in the active disease period for all the analyzed disorders, but only remained statistically significant in the acute leukemia and non-Hodgkin lymphoma groups during the remission period. Smaller differences were observed for the remaining lipid fractions, except for the triglyceride level, which increased in the active disease period in all the analyzed disorders except non-Hodgkin lymphoma. The most pronounced changes in the lipid fractions occurred in the HDL cholesterol level, and were the most remarkable for acute leukemia.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835–2738. doi: 10.1001/jama.256.20.2835. - DOI - PubMed
    1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344 (1994) 1383–1389. - PubMed
    1. Kreger B.E., Anderson K.M., Schatzkin A., Splansky G.L. Serum cholesterol level, body mass index, and the risk of colon cancer. The Framingham Study. Cancer. 1992;70:1038–1043. doi: 10.1002/1097-0142(19920901)70:5<1038::AID-CNCR2820700505>3.0.CO;2-M. - DOI - PubMed
    1. Sherwin R.W., Wentworth D.N., Cutler J.A., Hulley S.B., Kuller L.H., Stamler J. Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. JAMA. 1987;257:943–948. doi: 10.1001/jama.257.7.943. - DOI - PubMed
    1. Fiorenza A.M., Branchi A., Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int. J. Clin. Lab. Res. 2000;30:141–145. doi: 10.1007/s005990070013. - DOI - PubMed